Skip to main content
Jade Biosciences, Inc. logo

Jade Biosciences, Inc. — Investor Relations & Filings

Ticker · JBIO ISIN · US0080641071 US Professional, scientific and technical activities
Filings indexed 459 across all filing types
Latest filing 2026-06-03 Capital/Financing Update
Country US United States of America
Listing US JBIO

About Jade Biosciences, Inc.

https://jadebiosciences.com/

Jade Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases, inflammation, and immunology. The company aims to create transformative, disease-modifying treatments to address significant unmet medical needs and redefine the standard of care. Its pipeline features novel biologics, with the lead candidate, JADE101, being developed for the treatment of immunoglobulin A nephropathy (IgAN). JADE101 is an inhibitor of the cytokine APRIL (A PRoliferation-Inducing Ligand). The company's programs are based on discovery-stage assets licensed from Paragon Therapeutics.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 87% confidence The document is a preliminary prospectus supplement (Form 424(b)(5)) and accompanying prospectus relating to the offering of common stock and pre-funded warrants. It contains detailed terms of the offering, use of proceeds, underwriting arrangements, risk factors, dilution tables, and registered securities pricing. This is a formal capital raising document under SEC registration, not an earnings report, management discussion, or certificate. It falls squarely into the Capital/Financing Update category, which covers fundraising and financing activities.
2026-06-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed under the Securities Exchange Act, containing Regulation FD disclosure of a corporate slide presentation and interim Phase 1 clinical trial results. It is not an earnings release of financial results, not a proxy/material solicitation, nor an actual investor slide deck distributed outside the 8-K. The document itself is a regulatory filing that does not fit any more specific category, so it defaults to the miscellaneous Regulatory Filings category (RNS).
2026-06-01 English
424B3
Regulatory Filings Classification · 80% confidence The document is a Securities Act prospectus (Rule 424(b)(3)) for resale of registered shares by selling stockholders. It is not a financial report (10-K, IR), not an earnings release, not a management discussion, not a proxy statement, etc. It is a compliance filing with the SEC to register shares for resale, which best fits the “Regulatory Filings (RNS)” category as a general regulatory/compliance document.
2026-05-15 English
S-8 - Jade Biosciences, Inc. (0001798749) (Filer)
Regulatory Filings Classification · 85% confidence The document is a full SEC Form S-8 registration statement for Jade Biosciences to register shares under an employee inducement stock incentive plan. It is not an annual or quarterly report, earnings release, proxy, dividend notice, management/change announcement, or any of the other specific categories. It’s a regulatory form filing with the SEC, so it falls under the fallback category “Regulatory Filings (RNS).”
2026-05-07 English
S-3 - Jade Biosciences, Inc. (0001798749) (Filer)
Regulatory Filings Classification · 73% confidence The document is a long Form S-3 registration statement and prospectus filed with the U.S. SEC detailing the resale of previously issued shares by selling stockholders. It is not an Annual or Interim Report, nor an earnings release, call transcript, or a specific management or board announcement. It is a compliance/regulatory filing with substantive content (not merely a notice), for which there is no specialized category in the taxonomy. Therefore, it falls into the generic ‘Regulatory Filings’ category (RNS).
2026-05-07 English
S-3 - Jade Biosciences, Inc. (0001798749) (Filer)
Regulatory Filings
2026-05-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.